Lamotrigine Tablet, Film Coated, Extended Release
Product Images NDC 70518-4638

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 5 technical images submitted to the FDA as part of the official labeling for Lamotrigine (NDC 70518-4638). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Remedyrepack Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Mm1 (Lamotrigine 200mg 70518 4638 00)

Mm1 (Lamotrigine 200mg 70518 4638 00)
The text provides information about Lamotrigine tablets with an extended-release formula. It includes details such as the usual dosage recommendation, storage conditions (20-25°C), quantity per box (50), NDC number, and contact information for RemedyRepack Inc. This product is repackaged in Indiana, PA.*
FDA Label Image

Remedy_label (Remedy Label)

Remedy_label (Remedy Label)
This is a description of Lamotrigine tablet with usual dosage instructions, storage conditions, and lot details. It is a round blue tablet with "Y34" imprinted on it. The tablet is repackaged by RemedyRepack Inc. and for prescription use only.*
FDA Label Image

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)

Figure 1. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (primary Generalized Tonic-clonic Seizures Study) (Figure 1)
This text provides information about responder rates, improvement, and worsening in patients taking Placebo (N=73) and Lamotrigine (N=70). The data is presented in a visual format showing percentages of patients in different categories.*
FDA Label Image

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)

Figure 2. Proportion Of Patients By Responder Rate For Lamotrigine And Placebo Group (partial-onset Seizure Study) (Figure 2)
This is a table showing responder rates, improvements, and worsening effects of Lamotrigine compared to a placebo. The table provides data on the number of patients responding positively or negatively to the treatment in percentages.*
FDA Label Image

Chemical Structure (Graphic 01)

Chemical Structure (Graphic 01)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.